The global Non-Small Cell Lung Cancer (NSCLC) market size is expected to reach USD 13.51 Billion in 2030 and register a revenue CAGR of 6.8% during the forecast period. Increase in number of active smokers, rapid industrialization, and rise in global pollution level is driving the NSCLC market revenue growth. Occupational exposure to radiation and toxins such as asbestos is also contributing to increase in the incidence of NSCLC. Underground hard-rock miners and nuclear industry workers have been at increasing risk owing to radioactive radon, an inert gas, which can easily disperse through soils and rocks.
Lung cancer has resulted in a high mortality rate globally, which has led to need for effective treatment options. Rapid industrial development and sub-urbanization in Asian countries are contributing to increased prevalence of NSCLC and high demand for treatment. According to the American Cancer Society 2022, statistics for NSCLC was 82% of all lung cancer diagnoses in the U.S., and the five-year survival rate (All Surveillance, Epidemiology and End Results [SEER] stages combined) is 26%. Early-stage diagnosis can improve the 5-year survival rate to 80%, which is expected to have major positive implications for the prognosis of NSCLC tumors, thereby, significantly driving primary market leaders as well as government to focus on improvement of the efficacy of existing medicines and constant innovation of new therapies. Increase in funding for Research & Development (R&D), awareness initiatives, and an increase in approval of new innovative drugs by regulatory authorities are significantly contributing to revenue growth of the market. On 29 May 2021, Amgen announced that LUMAKRAS (sotorasib) has been approved by the Food and Drug Administration (FDA) for the treatment of adult patients affected with metastatic NSCLC or with KRAS G12C-mutated locally advanced.
Request a Sample@ https://qyresearchmedical.com/sample/119044
Higher adoption of targeted therapies, which is considered to be the foundation of precision medicine owing to R&D initiatives and a significant level of expertise in detecting malignant cells, is one of the primary factors driving growth of the market. Furthermore, technological advancements such as advanced imaging systems, minimally invasive robot surgeries, image-guided surgeries, and the development of novel drug therapeutics with fewer side effects are at forefront of cancer treatment modalities. However, side effects of drugs, availability of effective therapeutic methods, and limited treatment options are some of the major factors restraining growth of the market.
Driver: Increase in the prevalence of lung cancer
Around 25% of all cancer deaths are due to lung cancer, making it one of the leading causes of cancer death. Cigarette smoking, along with other environmental and genetic risk factors, has been recognized as a key risk factor for developing NSCLC. Approximately, 80% of lung cancer fatalities are caused by smoking, with the remainder being caused by secondhand smoke exposure. The World Health Organization predicts that lung cancer fatalities would continue to climb, owing mostly to an increase in global tobacco usage, particularly in Asia. Tobacco use is the primary risk factor for lung cancer and cigarette smoking is responsible for a high majority of all pulmonary carcinomas. Growing incidence of lung cancer can be attributed to water pollution, aging, radiation exposure, air pollution (polycyclic aromatic hydrocarbons), and long-term exposure to specific chemicals, gases, or pollutants such as asbestos, beryllium, arsenic, nickel, chromium, among others. Specific mutations have been identified for improved customized target treatment for patients with genetics and biomarker testing advancement, which have ample growth opportunities in the market. Various treatments such as radiation, surgery, targeted therapy, and chemotherapy are expected to drive market revenue growth over the forecast period.
Restraint: High cost of therapies and drugs
High cost of NSCLC drugs and therapies is a major restraint to the market growth. Various cost-intensive treatments such as immunotherapy, chemotherapy, and radiation therapy among others, including diagnosis, hospitalization, aftercare outpatient visits, and monthly initial repeated rounds therapy phase contribute to the overall treatment cost. Furthermore, the involvement of complex equipment and healthcare providers significantly increases the treatment cost, which is dependent on various key factors such as type or class of drugs administered, stage of cancer, treatment plan, and drug dosage. Increasing usage of biologics and targeted therapies is a major restraint for the NSCLC market as drugs come with myriads of side effects such as anemia, appetite loss, edema, and fertility issues, among others, and have a toxic effect on the body. Expensive medications during combination therapy and the extended stay at the hospitals are other factors expected to restrain market growth.
Individuals with NSCLC are highly prone to COVID-19 infection as the combination of disease and therapies, such as chemotherapy, results in a weakened immune system. Cancer patients are at an increased risk of death from COVID-19, as a combination of specific pathophysiological factors, such as underlying pulmonary impairment owing to smoking history and increasing specific pressures on respiratory healthcare services has been a constant challenge for treating patients with lung cancer safely. According to the Centers for Disease Control and Prevention (CDC), patients with certain chronic medical problems, such as cancer, are more susceptible to other serious diseases due to coronavirus. Rising demand for respiratory treatment in hospitals as a result of the pandemic contributes to this elevated risk.
Based on type, global NSCLC market has been segmented into adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others.
Adenocarcinoma segment revenue is expected to register a steady growth rate during the forecast period. Adenocarcinoma of the lung represents 40% of all lung cancers, which develop from the mucosal glands. Adenocarcinoma is the most common subtype to be diagnosed in non-smokers and women. Adenocarcinoma is common and least lethal of all kinds of lung cancer. Early-stage detection of adenocarcinoma provides for an easier NSCLC prognosis.
Squamous-cell carcinoma, contributing to 25% of NSCLC, develops from the early stages of squamous cells in airway epithelial cells located in bronchial tubes in the core of the lungs. Tobacco smoking is a major risk factor contributing to squamous-cell carcinoma. However, genetics also contribute as a risk factor as there has been an increasing incidence of individuals with family members affected with lung cancer. Early diagnosis for squamous-cell carcinoma highly increases the chances of getting cured.
Large cell carcinoma, which contributes to 10% of NSCLC, frequently develops in the central area of the lungs, spreading to adjacent lymph nodes, the chest walls, and distant organs. Increased consumption of tobacco is one of the major factors contributing to large cell carcinoma tumors.
Based on therapy, global NSCLC market has been segmented into chemotherapy, targeted therapy, surgery, radiotherapy, laser therapy, photodynamic therapy, immunotherapy, and others.
Immunotherapy segment revenue is expected to register a significantly large revenue growth rate during the forecast period. Immunotherapy in combination with other therapies is an emerging trend in the NSCLC market. Immunotherapy involving Immune Checkpoint Inhibitors (ICIs) is one of the key factors involved in the treatment of NSCLC as immunological checkpoint molecules such as Programmed Cell Death Ligand 1 (PD-1/PD-L1) and Cytotoxic T Lymphocyte-Associated Antigen (CTLA-4), which can dampen immune system responses and thus, acts as a negative regulator for T cells activation. Growing availability of multiple immunotherapy options and innovative development of cancer immunotherapy are some major factors driving revenue growth of the segment.
Radiation therapy revenue is expected to register a steady growth rate over the forecast period. Radiation therapy is emerging as a promising treatment as cancers that have spread to only one part of the body apart from the lungs, can be treated with help of radiation therapy, followed by regular cancer treatment. Need for Stereotactic Body Radiation Therapy (SBRT) as an alternative treatment to surgery is increasing among patients with Stage I NSCLC or individuals who cannot have surgery.
Drug Class Outlook:
Based on the drug class, global NSCLC market has been segmented into angiogenesis inhibitor, epidermal growth factor receptor inhibitor, kinase inhibitor, microtubule stabilizer, folate antimetabolites, PD-1/ PD-L1 inhibitor, and others.
Among various drug class segments in the market, the angiogenesis segment accounted for largest revenue share in 2021. The segment’s revenue growth is primarily driven by rising demand for more effective prevention of the formation of new blood vessels and more tailored medicines in both developed and emerging countries such as the US India, and Japan, among others.
Epidermal Growth Factor Receptor (EGFR) NSCLC causes cells to divide and multiply in an uncontrolled way due to genetic mutations, leading to cancer. EFGR-inhibitors such as erlotinib and cetuximab, among others, have been increasingly effective against unregulated cell division and continuous approval of improved drugs, are driving growth of the segment. On 21 May 2021, Janssen Pharmaceutical Companies of Johnson & Johnson was granted approval for Rybrevant, a bispecific antibody, by the Food and Drug Administration (FDA) for the treatment of epidermal growth factor-positive NSCLC with genetic mutations, exon 20 insertions. Further, on 4 April 2022, Health Canada issued a Notice of Compliance with Conditions (NOC/c) granting approval of Rybrevant for treatment of NSCLC patients (metastatic or locally advanced).
North America accounted for largest revenue share in global NSCLC market in 2021. Increased government fundings, presence of well-established healthcare sector with state-of-the-art R&D infrastructure are major factors expected to significantly increase market revenue growth in North America. Rapid adoption of advanced technologies and innovative treatments and therapies are also contributing to growth of the market.
Market in Europe is accounted for second largest revenue shareafter North America, driven by the R&D initiatives of key companies in the region. Furthermore, the presence of leading companies such as AstraZeneca, Roche, Novartis, and Sanofi as well as their active participation in the development of more innovative treatments is projected to support market growth.
The market in Asia Pacific is expected to register a steady revenue growth rate during the forecast period. Improving healthcare infrastructure, technological developments, and increase in R&D activities in the region are key factors expected to drive market growth. Increasing funding to healthcare facilities, and growing awareness regarding the availability of new therapies for treatment of cancer in countries such as China and India, are expected to drive market growth.
Competitive landscape of global NSCLC market is moderately consolidated with few key companies operating at global and regional levels. Major companies are engaged in R&D initiatives and testing, and entering into alliances to develop and introduce more novel and innovative products and devices.
Some major companies in global market report include AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffman-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., Novartis AG, Boehringer Ingelheim International GmbH, Sanofi, and Astellas Pharma Inc.
- On 19 April 2022, an antibody-drug conjugate, Enhertu was granted priority review by US Food and Drug Administration (FDA) for patients with previously treated HER2-mutant metastatic non-small cell lung cancer. Enhertu is being jointly developed by AstraZeneca and Daiichi Sankyo with a 54.9% tumor response rate. Enhertu is being further assessed in a comprehensive clinical development program evaluating efficiency and safety across multiple HER2-targetable cancers, including breast, gastric, lung, and colorectal cancers.
- On 8 March 2022, BioNTech and Regeneron expanded strategic collaboration to advance the clinical trials development of FixVac (BNT116) and Libtayo (cemiplimab) combination for the treatment of NSCLC. The companies plan to conduct advanced clinical trials for melanoma and prostate cancer patients, by combining complementary immunotherapies for new treatment options in high medical need areas.
Segments Covered in the Report
This report offers historical data and forecasts revenue growth at a global, regional, and country-level, and provides analysis of market trends in each of the sub-segments from 2022 to 2030. For this study, Reports and Data have segmented NSCLC market based on histology, treatment, drug class, and region:
Non-Small Cell Lung Cancer (NSCLC) Market Report Scope
Segments covered By Type Outlook, Therapy Outlook, Drug Class Outlook, Regional Outlook
By Type Outlook
Squamous cell carcinoma
Large cell carcinoma
By Therapy Outlook
By Drug Class Outlook
Epidermal Growth Factor Receptor Inhibitor
PD-1/ PD-L1 Inhibitor
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/119044/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: